Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 31.06 -0.64% -0.20
RYTM closed down 0.64 percent on Thursday, September 20, 2018, on 83 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical RYTM trend table...

Date Alert Name Type % Chg
Sep 20 50 DMA Resistance Bearish 0.00%
Sep 20 Fell Below 20 DMA Bearish 0.00%
Sep 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Sep 20 MACD Bullish Signal Line Cross Bullish 0.00%
Sep 20 Bollinger Band Squeeze Range Contraction 0.00%
Sep 19 50 DMA Resistance Bearish -0.64%
Sep 19 Crossed Above 20 DMA Bullish -0.64%
Sep 19 Spinning Top Other -0.64%
Sep 19 Bollinger Band Squeeze Range Contraction -0.64%
Sep 19 Up 3 Days in a Row Strength -0.64%

Older signals for RYTM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.23
52 Week Low 16.8
Average Volume 128,348
200-Day Moving Average 28.4758
50-Day Moving Average 31.3858
20-Day Moving Average 31.2315
10-Day Moving Average 31.006
Average True Range 1.4146
ADX 11.53
+DI 16.0191
-DI 20.873
Chandelier Exit (Long, 3 ATRs ) 30.3862
Chandelier Exit (Short, 3 ATRs ) 33.2638
Upper Bollinger Band 32.4744
Lower Bollinger Band 29.9886
Percent B (%b) 0.43
BandWidth 7.959272
MACD Line -0.1403
MACD Signal Line -0.1437
MACD Histogram 0.0034
Fundamentals Value
Market Cap 809.86 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -9.92
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.47
Resistance 3 (R3) 32.54 32.14 32.24
Resistance 2 (R2) 32.14 31.78 32.11 32.16
Resistance 1 (R1) 31.60 31.56 31.40 31.53 32.08
Pivot Point 31.20 31.20 31.10 31.17 31.20
Support 1 (S1) 30.66 30.84 30.46 30.59 30.04
Support 2 (S2) 30.26 30.62 30.23 29.96
Support 3 (S3) 29.72 30.26 29.89
Support 4 (S4) 29.65